Mandeep Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mandeep Kaur has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ravi Pratap Barnwal
Department of Biophysics, Panjab University
10 shared publications - Gurpal Singh
Panjab University
8 shared publications Janeka Gartia
School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University Campus 11, Bhubaneswar 751024 Odisha, India
3 shared publicationsAkanksha Sharma
Department of Biophysics, Panjab University, Sector-25, Chandigarh 160014, India
2 shared publications- Akanksha Sharma
Department of Biophysics, Panjab University
2 shared publications - Ganesan Senthil Kumar
Integrative Structural Biology Laboratory, National Institute of Immunology
2 shared publications
Latest Publications
- 3 November 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (22) , 4400-4416
Identifying Novel Spiro-Indenoquinoxaline-Pyrrolidine-Based Amyloid Beta Inhibitors in Alzheimer’s Disease from In Silico to In Vitro
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease characterized by memory loss and other cognitive functions. The key hallmarks of AD include extracellular beta-amyloid clumps and intracellular neurofibrillary tau tangles in the neurons. Cholinesterase inhibitors and NMDA-receptor antagonists and their combination are already approved treatments; however, these only give short-term symptom relief. Therefore, new therapeutic techniques and novel drugs are required to combat the century-old AD. This study includes the screening of nine novel small compounds (spiro-indenoquinoxaline-pyrrolidines) via in silico approaches; these compounds have been scrutinized to explore their potential as antiamyloidogenic drugs. Computational tools, including ADMET analysis, molecular docking, and molecular dynamics (MD) simulations, have been used for screening the selected compounds against monomeric peptides of Aβ (Aβ1-40 and Aβ1-42) and their oligomeric counterparts, i.e., 6Aβ9-40 and 6Aβ1-42. Among the nine molecules screened for this study, ADPR-d reflected the best drug-likeness and negligible toxicity. Further, ADPR-d has the highest binding affinity for all the peptides selected for this study. Additionally, MD simulations of Aβ peptide-ADPR-d complexes confirmed a stable complex formation. In vitro aggregation assay and cell culture studies for Aβ1-42 also support our in silico findings. The positive findings of the presented study highlight that the ADPR-d molecule may prove to be a potential therapeutic molecule against AD. However, these results would require further in vitro and in vivo analysis before proceeding to clinical settings with these compounds against AD.
- 3 November 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (22) , 4400-4416
Identifying Novel Spiro-Indenoquinoxaline-Pyrrolidine-Based Amyloid Beta Inhibitors in Alzheimer’s Disease from In Silico to In Vitro
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease characterized by memory loss and other cognitive functions. The key hallmarks of AD include extracellular beta-amyloid clumps and intracellular neurofibrillary tau tangles in the neurons. Cholinesterase inhibitors and NMDA-receptor antagonists and their combination are already approved treatments; however, these only give short-term symptom relief. Therefore, new therapeutic techniques and novel drugs are required to combat the century-old AD. This study includes the screening of nine novel small compounds (spiro-indenoquinoxaline-pyrrolidines) via in silico approaches; these compounds have been scrutinized to explore their potential as antiamyloidogenic drugs. Computational tools, including ADMET analysis, molecular docking, and molecular dynamics (MD) simulations, have been used for screening the selected compounds against monomeric peptides of Aβ (Aβ1-40 and Aβ1-42) and their oligomeric counterparts, i.e., 6Aβ9-40 and 6Aβ1-42. Among the nine molecules screened for this study, ADPR-d reflected the best drug-likeness and negligible toxicity. Further, ADPR-d has the highest binding affinity for all the peptides selected for this study. Additionally, MD simulations of Aβ peptide-ADPR-d complexes confirmed a stable complex formation. In vitro aggregation assay and cell culture studies for Aβ1-42 also support our in silico findings. The positive findings of the presented study highlight that the ADPR-d molecule may prove to be a potential therapeutic molecule against AD. However, these results would require further in vitro and in vivo analysis before proceeding to clinical settings with these compounds against AD.
- 11 December 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9502-9516
Computational insight into crucial interaction between Pcf11 and Ydh1 for pre-mRNA 3ˈ-end processing
Pre-mRNA processing in eukaryotes involves capping, splicing, cleavage, and polyadenylation. Various proteins regulating this key transcriptional event in humans share considerable homology with Saccharomyces cerevisiae proteins. Among these proteins, Pcf11 is a crucial component of the yeast CF IA sub-unit, and Ydh1 is part of the CPF sub-unit. Both these proteins have a significant role during the pre-mRNA processing of the nascent transcription. Our in silico analysis highlights probable interaction between residues of Pcf11-Ydh1 and their role in mRNA processing events. These outcomes provide evidence for direct interaction between the domain from residues 116 to 204 of Pcf11 (Pcf11116-204) with the N-terminal region of Ydh1 (residues 1-246; Ydh11-246). Molecular docking and MD simulations shed light on the structure and dynamics of the protein-protein complex that includes binding affinity and binding interface of Pcf11 and Ydh1 interaction. These outcomes would pave the way to further design in vitro and in vivo studies to determine the function of the Pcf11116-204 domain, which has not been previously analyzed; this would also facilitate deciphering the crucial role of Ydh1 and Pcf11 in assembling the cleavage and polyadenylation complex for executing co-transcriptional processing to generate mature mRNA.
- 11 December 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9502-9516
Computational insight into crucial interaction between Pcf11 and Ydh1 for pre-mRNA 3ˈ-end processing
Pre-mRNA processing in eukaryotes involves capping, splicing, cleavage, and polyadenylation. Various proteins regulating this key transcriptional event in humans share considerable homology with Saccharomyces cerevisiae proteins. Among these proteins, Pcf11 is a crucial component of the yeast CF IA sub-unit, and Ydh1 is part of the CPF sub-unit. Both these proteins have a significant role during the pre-mRNA processing of the nascent transcription. Our in silico analysis highlights probable interaction between residues of Pcf11-Ydh1 and their role in mRNA processing events. These outcomes provide evidence for direct interaction between the domain from residues 116 to 204 of Pcf11 (Pcf11116-204) with the N-terminal region of Ydh1 (residues 1-246; Ydh11-246). Molecular docking and MD simulations shed light on the structure and dynamics of the protein-protein complex that includes binding affinity and binding interface of Pcf11 and Ydh1 interaction. These outcomes would pave the way to further design in vitro and in vivo studies to determine the function of the Pcf11116-204 domain, which has not been previously analyzed; this would also facilitate deciphering the crucial role of Ydh1 and Pcf11 in assembling the cleavage and polyadenylation complex for executing co-transcriptional processing to generate mature mRNA.
- 2 November 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9375-9390
Deciphering significant interaction between Clp1 (CF IA) and Ssu72 (CPF) in pre-mRNA processing via in silico approaches
- 2 November 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (16) , 9375-9390
Deciphering significant interaction between Clp1 (CF IA) and Ssu72 (CPF) in pre-mRNA processing via in silico approaches
- 29 September 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (20) , 10978-10993
Screening of potential inhibitors against structural proteins from Monkeypox and related viruses of Poxviridae family via docking and molecular dynamics simulation
Monkeypox virus (MPXV) is an orthopoxvirus which causes zoonotic infection in humans. Even though sporadic cases of this infection are limited to the African continent, but if the infection continues to increase unabated, it can be a cause of serious concern for the human populace. Smallpox vaccination has been in use against monkeypox infection but it only provides mild protection. In the current study, we have screened novel small molecules (estrone fused heterocycles (EH1-EH7)) exhibiting good binding with monkeypox virus protein and related proteins from Poxviridae family of viruses via computational approaches. EH1-7 series of small molecules selected for the work have been synthesized via cycloaddition methodology. Docking and Molecular Dynamics (MD) results highlight EH4 compound to have strong binding affinity towards monkeypox and other related viral proteins selected for the study. Thus, computational outcomes suggest EH4 as a good candidate against monkeypox. Currently, no antiviral medication has been approved against monkeypox and the treatment is only via therapeutics available for smallpox and related conditions that may be helpful against monkeypox. Our study is thus an attempt to screen novel compounds against monkeypox infection, which would, in turn, facilitate development of novel therapeutics against Poxviridae family. HIGHLIGHTSMonkeypox infection is a public health emergency and necessitates immediate drug discovery.Molecular docking study to screen estrone-fused heterocycles compounds against Monkeypox and other orthopoxviruses.Molecular dynamics simulations revealed interaction/high binding affinities among EH4 heterocyclic compound and profilin-like protein from the monkeypox virus.Estrone-fused heterocycles compounds are promising anti-viral agents as per our in silico analysis.Our study provides evidence for investigating estrone-fused heterocycles compounds for further pharmacological interventions.Communicated by Ramaswamy H. Sarma.
- 29 September 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (20) , 10978-10993
Screening of potential inhibitors against structural proteins from Monkeypox and related viruses of Poxviridae family via docking and molecular dynamics simulation
Monkeypox virus (MPXV) is an orthopoxvirus which causes zoonotic infection in humans. Even though sporadic cases of this infection are limited to the African continent, but if the infection continues to increase unabated, it can be a cause of serious concern for the human populace. Smallpox vaccination has been in use against monkeypox infection but it only provides mild protection. In the current study, we have screened novel small molecules (estrone fused heterocycles (EH1-EH7)) exhibiting good binding with monkeypox virus protein and related proteins from Poxviridae family of viruses via computational approaches. EH1-7 series of small molecules selected for the work have been synthesized via cycloaddition methodology. Docking and Molecular Dynamics (MD) results highlight EH4 compound to have strong binding affinity towards monkeypox and other related viral proteins selected for the study. Thus, computational outcomes suggest EH4 as a good candidate against monkeypox. Currently, no antiviral medication has been approved against monkeypox and the treatment is only via therapeutics available for smallpox and related conditions that may be helpful against monkeypox. Our study is thus an attempt to screen novel compounds against monkeypox infection, which would, in turn, facilitate development of novel therapeutics against Poxviridae family. HIGHLIGHTSMonkeypox infection is a public health emergency and necessitates immediate drug discovery.Molecular docking study to screen estrone-fused heterocycles compounds against Monkeypox and other orthopoxviruses.Molecular dynamics simulations revealed interaction/high binding affinities among EH4 heterocyclic compound and profilin-like protein from the monkeypox virus.Estrone-fused heterocycles compounds are promising anti-viral agents as per our in silico analysis.Our study provides evidence for investigating estrone-fused heterocycles compounds for further pharmacological interventions.Communicated by Ramaswamy H. Sarma.
- 11 September 2023
- Published by Elsevier in Gene Reports
- Vol. 33
Clp1, an overexpressed subunit of CF IA and insights into its molecular role using biophysical approaches
- 11 September 2023
- Published by Elsevier in Gene Reports
- Vol. 33
Clp1, an overexpressed subunit of CF IA and insights into its molecular role using biophysical approaches
- 27 February 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (6) , 2491-2523
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
The development of early non-invasive diagnosis methods and identification of novel biomarkers are necessary for managing Alzheimer’s disease (AD) and facilitating effective prognosis and treatment. AD has multi-factorial nature and involves complex molecular mechanism, which causes neuronal degeneration. The primary challenges in early AD detection include patient heterogeneity and lack of precise diagnosis at the preclinical stage. Several cerebrospinal fluid (CSF) and blood biomarkers have been proposed to show excellent diagnosis ability by identifying tau pathology and cerebral amyloid beta (Aβ) for AD. Intense research endeavors are being made to develop ultrasensitive detection techniques and find potent biomarkers for early AD diagnosis. To mitigate AD worldwide, understanding various CSF biomarkers, blood biomarkers, and techniques that can be used for early diagnosis is imperative. This review attempts to provide information regarding AD pathophysiology, genetic and non-genetic factors associated with AD, several potential blood and CSF biomarkers, like neurofilament light, neurogranin, Aβ, and tau, along with biomarkers under development for AD detection. Besides, numerous techniques, such as neuroimaging, spectroscopic techniques, biosensors, and neuroproteomics, which are being explored to aid early AD detection, have been discussed. The insights thus gained would help in finding potential biomarkers and suitable techniques for the accurate diagnosis of early AD before cognitive dysfunction. Graphical Abstract
- 27 February 2023
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (6) , 2491-2523
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
The development of early non-invasive diagnosis methods and identification of novel biomarkers are necessary for managing Alzheimer’s disease (AD) and facilitating effective prognosis and treatment. AD has multi-factorial nature and involves complex molecular mechanism, which causes neuronal degeneration. The primary challenges in early AD detection include patient heterogeneity and lack of precise diagnosis at the preclinical stage. Several cerebrospinal fluid (CSF) and blood biomarkers have been proposed to show excellent diagnosis ability by identifying tau pathology and cerebral amyloid beta (Aβ) for AD. Intense research endeavors are being made to develop ultrasensitive detection techniques and find potent biomarkers for early AD diagnosis. To mitigate AD worldwide, understanding various CSF biomarkers, blood biomarkers, and techniques that can be used for early diagnosis is imperative. This review attempts to provide information regarding AD pathophysiology, genetic and non-genetic factors associated with AD, several potential blood and CSF biomarkers, like neurofilament light, neurogranin, Aβ, and tau, along with biomarkers under development for AD detection. Besides, numerous techniques, such as neuroimaging, spectroscopic techniques, biosensors, and neuroproteomics, which are being explored to aid early AD detection, have been discussed. The insights thus gained would help in finding potential biomarkers and suitable techniques for the accurate diagnosis of early AD before cognitive dysfunction. Graphical Abstract
- 27 September 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (16) , 7949-7965
Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs
SARS-CoV-2, the novel coronavirus spreading worldwide urges the need to repurpose drugs that can quickly enter clinical trials to combat the on-going global pandemic. A cluster of proteins are encoded for by the viral genome, each assuming a critical role in pathogen endurance inside the host. To handle the adverse circumstances, robust virtual strategies such as repurposing are coming to the fore due to being economical, efficient and rapid. Five FDA approved repurposed drugs proposed to act as inhibitors by targeting SARS-CoV-2 were used for initial evaluation via molecular docking. Moreover, a comparative analysis of the selected SARS-CoV-2 proteins against five ligands (Clemizole hydrochloride, Exemestane, Nafamostat, Pregnenolone and Umifenovir) was designed. In this regard, non-structural proteins (nsp3, nsp5, nsp10, nsp12 and nsp15), structural proteins (Spike, Nucleocapsid protein) and accessory proteins (ORF 3a, ORF 7a and ORF 9 b) were selected. Here, we aim to expedite the search for a potential drug from the five FDA approved repurposing drugs already in use for treatment of multiple diseases. Based on docking analysis, Umifenovir and Pregnenolone are suggested to show potential inhibitory effects against most of the SARS-CoV-2 proteins. These drugs are noteworthy since they exhibit high binding towards target proteins and should be used as lead compounds towards in vitro and in vivo studies. Communicated by Ramaswamy H. Sarma
- 27 September 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (16) , 7949-7965
Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs
SARS-CoV-2, the novel coronavirus spreading worldwide urges the need to repurpose drugs that can quickly enter clinical trials to combat the on-going global pandemic. A cluster of proteins are encoded for by the viral genome, each assuming a critical role in pathogen endurance inside the host. To handle the adverse circumstances, robust virtual strategies such as repurposing are coming to the fore due to being economical, efficient and rapid. Five FDA approved repurposed drugs proposed to act as inhibitors by targeting SARS-CoV-2 were used for initial evaluation via molecular docking. Moreover, a comparative analysis of the selected SARS-CoV-2 proteins against five ligands (Clemizole hydrochloride, Exemestane, Nafamostat, Pregnenolone and Umifenovir) was designed. In this regard, non-structural proteins (nsp3, nsp5, nsp10, nsp12 and nsp15), structural proteins (Spike, Nucleocapsid protein) and accessory proteins (ORF 3a, ORF 7a and ORF 9 b) were selected. Here, we aim to expedite the search for a potential drug from the five FDA approved repurposing drugs already in use for treatment of multiple diseases. Based on docking analysis, Umifenovir and Pregnenolone are suggested to show potential inhibitory effects against most of the SARS-CoV-2 proteins. These drugs are noteworthy since they exhibit high binding towards target proteins and should be used as lead compounds towards in vitro and in vivo studies. Communicated by Ramaswamy H. Sarma
- 16 August 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (34) , 15519-15528
Pseudo-Isolated α-Helix Platform for the Recognition of Deep and Narrow Targets
Although interest in stabilized α-helical peptides as next-generation therapeutics for modulating biomolecular interfaces is increasing, peptides have limited functionality and stability due to their small size. In comparison, α-helical ligands based on proteins can make steric clash with targets due to their large size. Here, we report the design of a monomeric pseudo-isolated α-helix (mPIH) system in which proteins behave as if they are peptides. The designed proteins contain α-helix ligands that do not require any covalent chemical modification, do not have frayed ends, and importantly can make sterically favorable interactions similar to isolated peptides. An optimal mPIH showed a more than 100-fold increase in target selectivity, which might be related to the advantages in conformational selection due to the absence of frayed ends. The α-helical ligand in the mPIH displayed high thermal stability well above human body temperature and showed reversible and rapid folding/unfolding transitions. Thus, mPIH can become a promising protein-based platform for developing stabilized α-helix pharmaceuticals.
- 16 August 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (34) , 15519-15528
Pseudo-Isolated α-Helix Platform for the Recognition of Deep and Narrow Targets
Although interest in stabilized α-helical peptides as next-generation therapeutics for modulating biomolecular interfaces is increasing, peptides have limited functionality and stability due to their small size. In comparison, α-helical ligands based on proteins can make steric clash with targets due to their large size. Here, we report the design of a monomeric pseudo-isolated α-helix (mPIH) system in which proteins behave as if they are peptides. The designed proteins contain α-helix ligands that do not require any covalent chemical modification, do not have frayed ends, and importantly can make sterically favorable interactions similar to isolated peptides. An optimal mPIH showed a more than 100-fold increase in target selectivity, which might be related to the advantages in conformational selection due to the absence of frayed ends. The α-helical ligand in the mPIH displayed high thermal stability well above human body temperature and showed reversible and rapid folding/unfolding transitions. Thus, mPIH can become a promising protein-based platform for developing stabilized α-helix pharmaceuticals.
- Open Access
- 31 January 2020
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 477 (2) , 491-508
Comparative structure, dynamics and evolution of acyl-carrier proteins from Borrelia burgdorferi, Brucella melitensis and Rickettsia prowazekii
Acyl carrier proteins (ACPs) are small helical proteins found in all kingdoms of life, primarily involved in fatty acid and polyketide biosynthesis. In eukaryotes, ACPs are part of the fatty acid synthase (FAS) complex, where they act as flexible tethers for the growing lipid chain, enabling access to the distinct active sites in FAS. In the type II synthesis systems found in bacteria and plastids, these proteins exist as monomers and perform various processes, from being a donor for synthesis of various products such as endotoxins, to supplying acyl chains for lipid A and lipoic acid FAS (quorum sensing), but also as signaling molecules, in bioluminescence and activation of toxins. The essential and diverse nature of their functions makes ACP an attractive target for antimicrobial drug discovery. Here, we report the structure, dynamics and evolution of ACPs from three human pathogens: Borrelia burgdorferi, Brucella melitensis and Rickettsia prowazekii, which could facilitate the discovery of new inhibitors of ACP function in pathogenic bacteria.
- 31 January 2020
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 477 (2) , 491-508
Open AccessComparative structure, dynamics and evolution of acyl-carrier proteins from Borrelia burgdorferi, Brucella melitensis and Rickettsia prowazekii
Acyl carrier proteins (ACPs) are small helical proteins found in all kingdoms of life, primarily involved in fatty acid and polyketide biosynthesis. In eukaryotes, ACPs are part of the fatty acid synthase (FAS) complex, where they act as flexible tethers for the growing lipid chain, enabling access to the distinct active sites in FAS. In the type II synthesis systems found in bacteria and plastids, these proteins exist as monomers and perform various processes, from being a donor for synthesis of various products such as endotoxins, to supplying acyl chains for lipid A and lipoic acid FAS (quorum sensing), but also as signaling molecules, in bioluminescence and activation of toxins. The essential and diverse nature of their functions makes ACP an attractive target for antimicrobial drug discovery. Here, we report the structure, dynamics and evolution of ACPs from three human pathogens: Borrelia burgdorferi, Brucella melitensis and Rickettsia prowazekii, which could facilitate the discovery of new inhibitors of ACP function in pathogenic bacteria.